What are the risks of MiPT?

Acute Toxicity No formal data in humans. Safety profile inferred from class membership and Shulgin's personal documentation (no adverse physiological effects reported at the doses he explored). Psychological Risks Standard tryptamine class risks. Psychosis contraindication applies. MAOI combination

How long does MiPT last?

The total duration of MiPT via oral is 3 hours to 8 hours.

MiPT — SubstanceWiki

N-Methyl-N-isopropyltryptamine (MiPT) is a synthetic psychedelic tryptamine featuring one methyl and one isopropyl group on the terminal nitrogen. It is the non-hydroxylated base compound corresponding to the more widely discussed 4-HO-MiPT (miprocin) and 4-AcO-MiPT — the 4-substituted variants that act as more potent psychedelics through 5-HT2A receptor activation. The unsubstituted MiPT has been documented by Alexander Shulgin in TiHKAL, where it was described as a psychedelic compound active in the 15–20 mg range orally.

Community documentation of MiPT base (as opposed to its 4-HO/4-AcO variants) is limited. The available data suggests psychedelic effects broadly consistent with the tryptamine class, though with a character that some distinguish from the 4-substituted analogs. The 4-hydroxy substitution in miprocin (4-HO-MiPT) substantially increases potency at 5-HT2A receptors, making the base MiPT less potent per milligram than its 4-HO counterpart.

Duration is reported in the 3–5 hour range. Like MET and DET, MiPT is expected to have partial oral bioavailability due to reduced MAO-A affinity relative to DMT, conferred by the isopropyl group.

How It Feels

The onset of MiPT is subtle and measured. Thirty to fifty minutes after ingestion, a gentle warmth begins to build in the body, accompanied by a very mild tingling in the extremities. The transition from baseline is gradual and undemanding — a slow, steady shift in the quality of awareness that feels more like a change in lighting than a change in channel. Colors may brighten marginally, and there is a growing sense of quiet presence, as though attention has been gently focused on the immediate moment.

As the experience develops over the next hour, the effects remain in the realm of the subtle. Visual changes are minimal: perhaps a soft enhancement of color, a slight increase in the apparent detail of textures, or a barely perceptible drift in surfaces. The primary effects are felt internally — a mild mood elevation, a gentle warmth of emotional tone, and a contemplative quality to thought that invites unhurried self-reflection. There is something cozy about the MiPT headspace; it creates a sense of inner comfort and quietude that is pleasant without being remarkable.

The peak, arriving around sixty to ninety minutes and lasting two to three hours, is a gentle plateau. The headspace is clear and accessible — conversations flow naturally, cognitive function is unimpaired, and there is no sense of disorientation or overwhelm. Music is subtly enhanced, carrying slightly more emotional weight than usual. Touch may be modestly heightened. The body feels warm and relaxed, with a mild but persistent pleasantness that pervades the physical experience. There is an introspective openness that makes it easy to sit with thoughts and feelings, examining them without the anxiety or intensity that stronger psychedelics sometimes provoke.

The comedown is smooth and gradual, the mild enhancement fading over one to two hours until baseline is reached without fanfare. The total duration is four to six hours. There is a subtle afterglow of warmth and contentment that may linger briefly. MiPT is among the mildest of the base tryptamines, offering a gentle, warm, and psychologically comfortable experience that serves as a quiet introduction to the tryptamine space — a substance of soft edges and understated character.

Detection Methods

Urine Detection

MiPT is not targeted by standard immunoassay-based urine drug screens. As a tryptamine, it is metabolized through monoamine oxidase pathways and produces hydroxylated and deaminated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The short duration of action of most base tryptamines results in a relatively brief detection window compared to longer-acting psychoactive substances.

Blood and Serum Detection

Blood detection windows for MiPT are short, typically 4 to 12 hours after oral administration. If smoked or insufflated, peak concentrations occur within minutes and clearance is more rapid. LC-MS/MS is required for reliable blood detection at the low concentrations characteristic of tryptamine compounds. The rapid metabolism by MAO-A significantly limits the time window in which blood sampling can capture meaningful concentrations.

Standard Drug Panel Inclusion

MiPT is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, or any other standard panel analyte. Detection requires specific testing at a reference laboratory capable of novel psychoactive substance analysis. Even extended clinical panels rarely include base tryptamines.

Confirmatory Methods

Confirmatory identification of MiPT relies on LC-MS/MS or GC-MS with appropriate reference standards. GC-MS analysis of tryptamines may require derivatization for optimal sensitivity and chromatographic performance. Reference laboratories specializing in novel psychoactive substances provide the most comprehensive detection capabilities. Standard clinical toxicology laboratories generally do not maintain validated methods for base tryptamines.

Reagent Testing (Harm Reduction)

The Ehrlich reagent produces a purple to violet reaction with MiPT, confirming the presence of an indole ring system. This is the primary field identification tool and should be used as the first screening test. The Hofmann reagent provides a confirmatory blue to purple reaction. The Marquis reagent typically shows no reaction or a slight brown-yellow discoloration with base tryptamines. A positive Ehrlich result confirms the tryptamine class but does not identify the specific compound. Multiple reagents should be used together for greater confidence in identification.

Interactions

Substance	Status	Note
2-Aminoindane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FEA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2,5-DMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-H	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FEA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FPM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3,4-CTMP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4F-EPH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4F-MPH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
5-APB	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
5F-AKB48	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
5F-PB-22	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
6-APDB	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
A-PHP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
A-PVP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
AB-FUBINACA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Amphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Armodafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Butylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Caffeine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Cannabis	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Cocaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cyclazodone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Desoxypipradrol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dextroamphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
ETH-CAT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ethylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ethylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Fenethylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Isopropylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
JWH-018	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
JWH-073	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Kratom	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lisdexamfetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MAOI	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
MCPP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDPV	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mephedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methamphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methiopropamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylnaphthidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mirtazapine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Modafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Myristicin	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
N-Ethylhexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
N-Methylbisfluoromodafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
NEP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
NM-2-AI	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Pentedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
1B-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-AL-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-MiPLA	Low Risk & Synergy	Cross-tolerance exists; effects compound
1P-ETH-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1P-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1V-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
2-Fluorodeschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
25B-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25B-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25C-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25C-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25D-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25I-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25I-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25N-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-B	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-B-FLY	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-C	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-D	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-E	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-I	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-P	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3C-E	Low Risk & Synergy	Cross-tolerance exists; effects compound
3C-P	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
5-MeO-DALT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DiBF	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
6-APB	Low Risk & Synergy	Cross-tolerance exists; effects compound
AL-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
ALD-52	Low Risk & Synergy	Cross-tolerance exists; effects compound
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Bromo-DragonFLY	Low Risk & Synergy	Cross-tolerance exists; effects compound
Bufotenin	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Dextromethorphan	Low Risk & Synergy	Produces unique synergistic effects; often combined
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOB	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOC	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOI	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Escaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
ETH-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
LAE-32	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSA	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSM-775	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSZ	Low Risk & Synergy	Cross-tolerance exists; effects compound
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
Mescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methoxetamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
Methoxphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MiPLA	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
Nitrous	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PARGY-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
PRO-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Codeine	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Fentanyl	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Heroin	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Morphine	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Oxycodone	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Alcohol	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Alprazolam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Clonazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Diazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
GHB	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 197 key interactions out of 240 total.

Full	almost immediately after ingestion
Half	3 days
Zero	7 days

MiPT

Quick Dosage

Dosage

oral

Duration

How It Feels

Subjective Effects

Cognitive & Perceptual Effects

Visual(1)

Cognitive(2)

Pharmacology

5-HT2A Partial Agonism

Oral Activity

Relationship to 4-HO-MiPT

Pharmacokinetics

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Shulgin Documentation

Community Context

Harm Reduction

Dosing

Distinguish from 4-HO-MiPT

Standard Psychedelic Harm Reduction

Toxicity & Safety

Acute Toxicity

Psychological Risks

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (6)

Community Discussions (1)

See Also

References (6)

Frequently Asked Questions